AADI BIOSCIENCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.75 USD | +4.17% |
|
-4.89% | -13.37% |
| Mar. 13 | Transcript : Aadi Bioscience, Inc., Q4 2023 Earnings Call, Mar 13, 2024 | |
| Mar. 13 | Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $6.3M | MT |
Presenter SpeechFrank Tang (Analysts)Good morning, everyone. I am Frank Chang from the Morgan ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. It has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.75
USD
Average target price
11.67
USD
Spread / Average Target
+566.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.37% | 42.97M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- AADI Stock
- News Aadi Bioscience, Inc.
- Transcript : Aadi Bioscience, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 09
